NCT06905483View on ClinicalTrials.gov

Comparative Effects of Triple Inhaled Therapy With Budesonide/Glycopyrronium/Formoterol Versus Fluticasone Furoate/Umeclidinium/Vilanterol on Small Airway Disease in COPD Patients: A Randomized Crossover Study

PHASE4RecruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

April 1, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

March 31, 2026

Conditions
COPDChronic Obstructive Pulmonary Disease (COPD)Small Airway DiseaseTriple TherapyLung Function
Interventions
DRUG

Budesonide/Glycopyrronium/Formoterol (BGF)

Each patient received 4 weeks of treatment with either BGF or FUV followed by a 1-week washout period, and then 4 weeks of treatment with the other drug.

DRUG

Fluticasone Furoate/Umeclidinium/Vilanterol (FUV)

Each patient received 4 weeks of treatment with either BGF or FUV followed by a 1-week washout period, and then 4 weeks of treatment with the other drug.

Trial Locations (1)

12120

RECRUITING

Narongkorn Saiphoklang, Pathum Thani

All Listed Sponsors
lead

Thammasat University

OTHER